Physician profile
David C Lash
NPI 1992804363
$5,236.25
in general payments reported to CMS, 2019-2025
43 companies · $84.68 in 2025
The $84.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $179 · 2021: $841 · 2022: $1,388 · 2023: $1,218 · 2024: $221 · 2025: $84.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.04 | 2019-2025 | |
| Novo Nordisk INC | $444.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $437.50 | 2019-2024 | Mounjaro |
| Pfizer INC. | $403.24 | 2019-2024 | |
| Amgen INC. | $374.25 | 2019-2022 | |
| Astellas Pharma US INC | $299.97 | 2019-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $253.86 | 2021 | |
| Glaxosmithkline, LLC. | $251.95 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $227.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $145.07 | 2021-2024 | Spravato |
| Merck Sharp & Dohme LLC | $128.17 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Acadia Pharmaceuticals INC | $119.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.25 | 2021-2023 | |
| Medtronic, INC. | $112.38 | 2021 | |
| Amarin Pharma, INC. | $106.18 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.